Caregen, a biotechnology company, is accelerating its conquest of the global beauty and plastic surgery market. Caregen announced that it successfully completed the 'IMCAS World Congress 2025' (International Master Course on Aging Science) held at the Palais des Congrès de Paris, France from January 30 to February 1.
IMCAS is a global academic conference where dermatologists, plastic surgeons, and industry experts from around the world share the latest aesthetic and plastic surgery trends and technologies. It is a global event attended by over 15,000 medical professionals and industry professionals every year.
Caregen participated in this conference as a Platinum Sponsor and unveiled a number of its representative innovative products and research and development (R&D) results.
At this IMCAS, Caregen attracted great attention from industry insiders by introducing its representative dermal filler and hair filler products, such as 'DR. CYJ Hair Filler', 'CG DimonoPTx, and Revofil'. Throughout the event, medical professionals and industry experts from all over the world visited the Caregen booth, which was packed. In particular, it revealed Korglutide, an oral weight control agent for GLP-1 series currently under clinical development, suggesting the possibility of entering the obesity treatment market. 'Korglutide' is an innovative peptide-based product involved in weight loss and metabolism control, and has strengths that differentiate it from GLP-1 series treatments that are in high demand in the global market. Furthermore, as the possibility of first launching GLP-1 series oral weight control agents in the form of health functional foods was highlighted, expectations in the industry have increased even more. The attention of related industries and partners was focused on the possibility of expanding consumer accessibility and rapidly strengthening influence in the global market. Through this, Caregen is expected to create new growth opportunities in the functional healthcare market.
Caregen invited its major global partners to the IMCAS site to host 'Caregen Bio Night', introducing its R&D pipeline and sharing its global market expansion strategy. In addition, it presented the slogan, "Live Caregen, Live Longer!", conveying the message that Caregen's innovative biotechnology and products can help people maintain a healthy life and extend their lifespan, and showed its active will to expand into the global market.
Caregen is continuously strengthening its marketing through various global exhibitions and exhibitions including IMCAS, thereby expanding its global network. Thanks to these efforts, interest from local European private equity (PE) investors is gradually increasing, and in particular, they are paying attention to Caregen’s research and development (R&D) capabilities and differentiated technological prowess.
In particular, Caregen has established a solid position in the European beauty and plastic surgery market, and based on its innovative product portfolio, PE investors are seeking the possibility of a long-term strategic partnership rather than a simple financial investment. Currently, some PE investors are discussing the possibility of cooperation for product development and overseas market expansion, which will be an opportunity to further strengthen Caregen's global market competitiveness.
Caregen's R&D pipeline is positioned as a key driving force for leading the global healthcare market based on continuous innovation. The development of next-generation products using advanced biotechnology is accelerating, and this is expected to further expand the company's growth potential and market influence. Caregen plans to continue to introduce innovative bio products through active R&D and global network expansion, and establish itself as a leading company in the global healthcare market.
Caregen's exhibition participation status and various corporate activities can be checked through Caregen's official Instagram (@caregen.official), and product information and news related to global partnerships will also be continuously updated.
- See more related articles
You must be logged in to post a comment.